Skip to main content
SpringerLink
Log in

The Benefits of Stopping Smoking and the Role of Nicotine Replacement Therapy in Older Patients

  • Review Article
  • Drug Therapy
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Considerable benefits accrue from stopping smoking in older patients. Reversal of the short term cardiovascular adverse effects of smoking is rapid. Long term risk reduction appears to occur as a resuit of decreased life-time exposure to tobaceo smoke.

The pharmacology of nicotine has not been studied in older patients but is unlikely to change in clinically important ways with advancing age. Nicotine replacement doubles long term success rates, compared with placebo, among younger smokers of ≥10 cigarettes per day. There is no reason to believe its efficacy should be less among older smokers.

Transdermal nicotine is the replacement therapy of choice in older patients because of once-daily administration and good tolerability. Approximately half of the users of transdermal nicotine smoke concurrently with treatment. It is unlikely that concurrent smoking or high doses of nicotine replacement therapy will adversely effect healthy patients. While it is generally believed that patients with unstable coronary heart disease may be at risk from concurrent smoking during nicotine replacement therapy, it is unclear whether this risk is greater than the risk of smoking alone.

Nicotine replacement therapy is a logical approach for motivated, older smokers who are unable to stop smoking by simpler means. Results can be augmented by including other interventions, such as counselling and follow-up support.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. US Department of Health and Human Services. The health consequences of smoking and nicotine addiction: a report of the Surgeon General, 1988. Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1988: DHHS Publication No. (CDC) 88-8406

  2. Houezec J, Benowitz NL. Basic and clinical psychopharmacology of nicotine. Clin Chest Med 1991; 12: 681–699

    PubMed  Google Scholar 

  3. Benowitz NL. Pharmacologic aspects of smoking. N Engl J Med 1988; 319: 1318–30

    PubMed  CAS  Google Scholar 

  4. Benowitz NL. Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol 1996; 36: 597–613

    PubMed  CAS  Google Scholar 

  5. Maxwell CJ, Hirdes JP. The prevalence of smoking and implications for the quality of life among the community-based elderly. Am J Prev Med 1993; 9: 338–45

    PubMed  CAS  Google Scholar 

  6. US Department of Health and Human Services. Cigarette smoking among adults: United States, 1991. MMWR Morbid Mortal Wkly Rep 1993; 42: 230–3

    Google Scholar 

  7. Risk Factor Prevalence Study Management Committee. Risk factor prevalence study: survey no. 3 1989. Canberra: National Heart Foundation of Australia and Australian Institute of Health, 1990

    Google Scholar 

  8. University of California, San Diego. Tobacco use in California, 1990–1991. Sacramento: California Department of Health Services, 1992

    Google Scholar 

  9. Gourlay SG, Forbes A, Marriner T, et al. A prospective study of factors predicting smoking cessation using transdermal nicotine therapy. BMJ 1994; 309: 842–6

    PubMed  CAS  Google Scholar 

  10. Gourlay SG, McNeil JJ. Antismoking products. Med J Aust 1990; 153: 699–707

    PubMed  CAS  Google Scholar 

  11. Doll R, Peto R, Wheatley K, et al. Mortality in relation to smoking: 40 years’ observations on male British doctors. BMJ 1994; 309: 901–11

    PubMed  CAS  Google Scholar 

  12. Mellstrom D, Rundgren A, Jagenburg R, et al. Tobacco smoking, ageing and health among the elderly: a longitudinal study of 70-year-old men and an age cohort comparison. Age Ageing 1982; 11:45–58

    PubMed  CAS  Google Scholar 

  13. Colsher PL, Wallace RB, Pomrehn PR, et al. Demographic and health characteristics of elderly smokers: results from established populations for epidemiologic studies of the elderly. Am J Prev Med 1990; 6: 61–70

    PubMed  CAS  Google Scholar 

  14. Daling JR, Sherman KJ, Hislop G, et al. Cigarette smoking and the risk of anogenital cancer. Am J Epidemiol 1992; 135: 180–9

    PubMed  CAS  Google Scholar 

  15. Brownson RC, Novotny TE, Perry MC. Cigarette smoking and adult leukemia. Arch Intern Med 1993; 153: 469–75

    PubMed  CAS  Google Scholar 

  16. US Department of Health and Human Services. The health benefits of smoking cessation: a report of the Surgeon General, 1990. US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1990: DHHS Publication No. (CDC) 90-8416

  17. Rose G, Shipley M. Effects of coronary risk reduction on the pattern of mortality. Lancet 1990; 335: 275–7

    PubMed  CAS  Google Scholar 

  18. Benfante R, Reed D, Frank J. Does cigarette smoking have an independent effect on coronary heart disease incidence in the elderly? Am J Public Health 1991; 81: 897–9

    PubMed  CAS  Google Scholar 

  19. LaCroix AZ, Lang J, Scherr P, et al. Smoking and mortality among older men and women in three communities. N Engl J Med 1991; 324: 1619–25

    PubMed  CAS  Google Scholar 

  20. Jajich CL, Ostfeld AM, Freeman DH. Smoking and coronary heart disease mortality in the elderly. JAMA 1984; 252: 2831–4

    PubMed  CAS  Google Scholar 

  21. Harris T, Cook EF, Kannel WB, et al. Proportional hazards analysis of risk factors for coronary heart disease in individuais aged 65 or older. J Am Geriatr Soc 1988; 36: 1023–8

    PubMed  CAS  Google Scholar 

  22. Omenn GS, Hermanson B, Kronmal RA. Smoking cessation in older patients with coronary artery disease [letter]. N Engl J Med 1989; 320: 1149

    Google Scholar 

  23. Hermanson B, Omenn GS, Kronmal RA, et al. Beneficiai six-year outcome of smoking cessation in older men and women with coronary artery disease. N Engl J Med 1988; 319: 1365–9

    PubMed  CAS  Google Scholar 

  24. Deanfield JE, Shea MJ, Wilson RA, et al. Direct effects of smoking on the heart: silent myocardial ischemic disturbances of coronary flow. Am J Cardiol 1986; 57: 1005–9

    PubMed  CAS  Google Scholar 

  25. Sugiishi M, Takatsu F. Cigarette smoking is a major risk factor for coronary spasm. Circulation 1993; 87: 76–9

    PubMed  CAS  Google Scholar 

  26. Winniford MD, Jansen DE, Reynolds GA, et al. Cigarette smoking-induced coronary vasoconstriction in atherosclerotic coronary artery disease and prevention by calcium antagonists and nitroglycerin. Am J Cardiol 1987; 59: 203–7

    PubMed  CAS  Google Scholar 

  27. Moreyra AE, Lacy CR, Wilson AC, et al. Arterial blood nicotine concentration and coronary vasoconstrictive effect of lownicotine cigarette smoking. Am Heart J 1992; 124: 392–7

    PubMed  CAS  Google Scholar 

  28. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ 1989; 298: 784–8

    PubMed  CAS  Google Scholar 

  29. Freeman DJ, Griffin BA, Murray E, et al. Smoking and plasma lipoproteins in man: effects of low density lipoprotein cholesterol and high density lipoprotein subfraction distribution. Eur J Clin Pharm 1993; 23: 630–40

    CAS  Google Scholar 

  30. Scheffler E, Wiest E, Woehrle J, et al. Smoking influences the atherogenic potential of low-density lipoprotein. Clin Investig 1992; 70: 263–8

    PubMed  CAS  Google Scholar 

  31. Morrow JD, Frei B, Longmire AW, et al. Increase in circulating products of lipid peroxidation (F2–isoprostanes) in smokers. N Engl J Med 1995; 332: 1198–203

    PubMed  CAS  Google Scholar 

  32. Celermajer DS, Sorensen KE, Georgakopoulos D, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993; 88: 2149–55

    PubMed  CAS  Google Scholar 

  33. Smith FB, Lowe GDO, Fowkes FGR, et al. Smoking, haemostatic factors and lipid peroxides in a population case control study of peripheral arterial disease. Atherosclerosis 1993; 102: 155–62

    PubMed  CAS  Google Scholar 

  34. McGill HC. The cardiovascular pathology of smoking. Am Heart J 1988; 115: 250–7

    PubMed  Google Scholar 

  35. Kario K, Matsuo T, Nakao K. Cigarette smoking increases the mean platelet volume in elderly patients with risk factors for atherosclerosis. Clin Lab Haematol 1992; 14: 281–7

    PubMed  CAS  Google Scholar 

  36. Salbas K. Effect of acute smoking on red blood cell deformability in healthy young and elderly non-smokers, and effect of verapamil on age- and acute smoking-induced change in red blood cell deformability. Scand J Clin Lab Invest 1994; 54: 411–16

    PubMed  CAS  Google Scholar 

  37. Kannel WB, D’Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and the risk of cardiovascular disease: insights from the Framingham study. Am Heart J 1987; 113: 1006–10

    PubMed  CAS  Google Scholar 

  38. Feher MD, Rampling MW, Brown J, et al. Acute changes in atherogenic and thrombogenic factors with cessation of smoking. J R Soc Med 1990; 83: 146–8

    PubMed  CAS  Google Scholar 

  39. Rabkin SW. Effect of cigarette smoking cessation on risk factors for coronary atherosclerosis. Arteriosclerosis 1984; 53: 173–84

    CAS  Google Scholar 

  40. Cole CW, Hill GB, Farzad E, et al. Cigarette smoking and peripheral arterial occlusive disease. Surgery 1993; 114: 753–7

    PubMed  CAS  Google Scholar 

  41. Fowkes FGR, Housley E, Riemersma RA, et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh artery study. Am J Epidemiol 1993; 135:331–40

    Google Scholar 

  42. Witteman JCM, Grobbee DE, Valkenburg HA, et al. Cigarette smoking and the development and progression of aortic atherosclerosis. Circulation 1993; 88: 2156–62

    PubMed  CAS  Google Scholar 

  43. Pathobiological Determinants of Atherosclerosis in Youth Research Group. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. JAMA 1990; 264: 3018–24

    Google Scholar 

  44. Tell GS, Howard G, McKinney WM, et al. Cigarette smoking cessation and extracranial carotid atherosclerosis. JAMA 1989; 261: 1178–80

    PubMed  CAS  Google Scholar 

  45. Cook DG, Shaper AG, Pocock SJ, et al. Giving up smoking and the risk of heart attacks. Lancet 1986; II: 1376–80

    Google Scholar 

  46. Dempsey RJ, Moore RW. Amount of smoking independently predicts carotid artery atherosclerosis severity. Stroke 1992; 23: 693–6

    PubMed  CAS  Google Scholar 

  47. Rivers JT, White HD, Cross DB, et al. Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management: incidence and effect of smoking. J Am Coll Cardiol 1990; 16: 340–8

    PubMed  CAS  Google Scholar 

  48. Galan KM, Deligonul U, Kern MJ, et al. Increased frequency of restenosis in patients continuing to smoke cigarettes after percutaneous transluminal coronary angioplasty. Am J Cardiol 1988; 61: 260–3

    PubMed  CAS  Google Scholar 

  49. Cavender JB, Rogers WJ, Fisher LD, et al. Effects of smoking on survival and morbidity in patients randomised to medical or surgical therapy in the coronary artery surgery study (CASS): 10 year follow-up. J Am Coll Cardiol 1992; 20: 287–94

    PubMed  CAS  Google Scholar 

  50. Rose G, Hamilton PJS, Colwell L, et al. A randomised controlled clinical trial of anti-smoking advice: 10-year results. J Epidemiol Community Health 1982; 36: 102–8

    PubMed  CAS  Google Scholar 

  51. Rogers RL, Meyer JS, Judd BW, et al. Abstention from cigarette smoking improves cerebral perfusion among elderly chronic smokers. JAMA 1985; 253: 2970–4

    PubMed  CAS  Google Scholar 

  52. Donnan GA, McNeil JJ, Adena MA, et al. Smoking as a risk factor for cerebral ischaemia. Lancet 1989; II: 643–7

    Google Scholar 

  53. Homer D, Ingall TJ, Baker Jr HL, et al. Serum lipoproteins are less powerful predictors of extracranial carotid artery atherosclerosis than are cigarette smoking and hypertension. Mayo Clin Proc 1991; 66: 259–67

    PubMed  CAS  Google Scholar 

  54. Buhler FR, Vesanen K, Watters JT, et al. Impact of smoking on heart attacks, strokes, blood pressure control, drug dose, and quality of life aspects in the international prospective primary prevention study in hypertension. Am Heart J 1988; 115: 282–8

    PubMed  CAS  Google Scholar 

  55. Whisnant JP, Homer D, Ingall TJ, et al. Duration of cigarette smoking is the strongest predictor of severe extracranial carotid artery atherosclerosis. Stroke 1990; 21: 707–14

    PubMed  CAS  Google Scholar 

  56. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989; 298: 789–94

    PubMed  CAS  Google Scholar 

  57. Rogot E, Murray JL. Smoking and causes of death among US veterans: 16 years of observation. Public Health Rep 1980; 95:213–22

    PubMed  CAS  Google Scholar 

  58. Quick CRG, Cotton LT. The measured effect of stopping smoking on intermittent claudication. Br J Surg 1982; 69: S24–6

    PubMed  Google Scholar 

  59. Faulkner KW, House AK, Castleden WM. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. Med J Aust 1983; 1:217–9

    PubMed  CAS  Google Scholar 

  60. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Acta Med Scand 1987; 221: 253–60

    PubMed  CAS  Google Scholar 

  61. Lepäntalo M, Lassila R. Smoking and occlusive peripheral artery disease. Eur J Surg 1991; 157: 83–7

    PubMed  Google Scholar 

  62. Myers KA, King RB, Scott DF, et al. The effect of smoking on the late patency of arterial reconstructions in the legs. Br J Surg 1978; 65: 267–71

    PubMed  CAS  Google Scholar 

  63. Wetzig GA, Gough IR, Furnival CM. One hundred cases of arteriovenous fistula for haemodialysis access: the effect of cigarette smoking on patency. Aust NZ J Surg 1985; 55: 551–4

    CAS  Google Scholar 

  64. Peto R, Lopez AD, Boreham J, et al. Mortality from smoking in developed countries 1950–2000. Oxford: Oxford Univer-sity Press, 1994

    Google Scholar 

  65. Lubin JH, Blot WJ. Lung cancer and smoking cessation: patterns of risk. J Natl Cancer Inst 1993; 85: 422–3

    PubMed  CAS  Google Scholar 

  66. Sobue T, Yamaguchi N, Suzuki T, et al. Lung cancer incidence rate for maie ex-smokers according to age at cessation of smoking. Jpn J Cancer Res 1993; 84: 601–7

    PubMed  CAS  Google Scholar 

  67. Halpern MT, Gillespie BW, Warner KE. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst 1993; 85: 457–64

    PubMed  CAS  Google Scholar 

  68. Richardson GE, Tucker MA, Venzon DJ, et al. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med 1993; 119: 383–90

    PubMed  CAS  Google Scholar 

  69. Gregg I, Nunn AJ. Peak expiratory flow in symptomless elderly smokers and ex-smokers. BMJ 1989; 298: 1071–2

    PubMed  CAS  Google Scholar 

  70. Higgins MW, Enright PL, Kronmal RA, et al. Smoking and lung function in elderly men and women. JAMA 1993; 269: 2741–8

    PubMed  CAS  Google Scholar 

  71. Sherrill DL, Lebowitz MD, Knudson RJ, et al. Longitudinal methods for describing the relationship between pulmonary function, respiratory Symptoms and smoking in elderly subjects: the Tuscon study. Eur Respir J 1993; 6: 342–8

    PubMed  CAS  Google Scholar 

  72. Warner MA, Offord KP, Warner ME, et al. Role of preoperative cessation of smoking and other factors in postoperative pulmonary complications: a blinded prospective study of coronary artery bypass surgery. Mayo Clin Proc 1989; 64: 609–16

    PubMed  CAS  Google Scholar 

  73. Salive ME, Cornoni-Huntley J, LaCroix AZ, et al. Predictors of smoking cessation and relapse in older adults. Am J Public Health 1992; 82: 1268–71

    PubMed  CAS  Google Scholar 

  74. Fiore MC, Novotny TE, Pierce JP et al. Methods used to quit smoking in the United States. JAMA 1990; 263: 2760–5

    PubMed  CAS  Google Scholar 

  75. Hatsukumi D, Hughes JR, Pickens R. Characterisation of tobacco withdrawal: physiological and subjective effects. In: Grabowski J, Hall SM, editors. Pharmcological adjuncts in smoking cessation. Research monograph 53. US Department of Health and Human Services, National Institute on Drug Abuse, 1985: DHHS Publication No. (ADM) 85-1333

    Google Scholar 

  76. American Psychiatrie Association. Diagnostic and statistical manual of psychiatric disorders. 4th ed. Washington DC: American Psychiatrie Association, 1994

    Google Scholar 

  77. Mattick RP, Baillie A, Grenyer B, et al. An outline for approaches to smoking cessation: quality assurance project [NCADA Monograph No. 19]. Mattick RP, Baillie A, editors. Canberra: Australian Government Publishing Service, 1992: 15–50

  78. Foulds J, Stapleton J, Feyerabend C, et al. Effect of transdermal nicotine patches on cigarette smoking: a double blind crossover study. Psychopharmacology 1992; 106: 421–7

    PubMed  CAS  Google Scholar 

  79. Levin ED, Westman EC, Stein RM, et al. Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates rewarding effects of smoking. J Clin Psychopharmacol 1994; 14: 41–9

    PubMed  CAS  Google Scholar 

  80. Fagerström KO. Measuring the degree of physical dependence to tobacco smoking with reference to individualisation of treatment. Addict Behav 1978; 3: 235–41

    PubMed  Google Scholar 

  81. Niaura R, Goldstein MG, Abrams DB. Matching high- and lowdependence smokers to self-help treatment with or without nicotine replacement. Prev Med 1994; 23: 70–7

    PubMed  CAS  Google Scholar 

  82. Blondal T. Controlled trial of nicotine polacrilex gum with supportive measures. Arch Intern Med 1989; 149: 1818–21

    PubMed  CAS  Google Scholar 

  83. Hjalmarson A, Franzon M, Westin A, et al. Effect of nicotine nasal spray on smoking cessation. Arch Intern Med 1994; 154: 2567–72

    PubMed  CAS  Google Scholar 

  84. Sachs DP, Säwe U, Leischow SJ. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group therapy. Arch Intern Med 1993; 153: 1881–90

    PubMed  CAS  Google Scholar 

  85. Gourlay SG, Benowitz NL. Is clonidine an effective smoking cessation therapy? Drugs 1995; 50: 197–207

    PubMed  CAS  Google Scholar 

  86. Rose JE, Behm FM, Westman EC, et al. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 1994; 56: 86–9

    PubMed  CAS  Google Scholar 

  87. Orleans CT, Resch N, Noll E, et al. Use of transdermal nicotine in a state-level prescription plan for the elderly: a first look at ‘real world’ patch users. JAMA 1994; 271: 601–7

    PubMed  CAS  Google Scholar 

  88. Haxby D, Sinclair A, Eiff MP, et al. Characteristics and perceptions of nicotine patch users. J Fam Pract 1994; 38: 459–64

    PubMed  CAS  Google Scholar 

  89. Benowitz NL, Jacob III P. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 1994; 56: 483–93

    PubMed  CAS  Google Scholar 

  90. Roskos KV, Maibach HI, Bircher AJ, et al. The effect of aging on percutaneous absorption in man. J Pharmacokinet Biopharm 1989; 17: 617–30

    PubMed  CAS  Google Scholar 

  91. Fiore MC, Jorenby DE, Baker TB, et al. Tobacco dependence and the nicotine patch. JAMA 1992; 268: 2687–94

    PubMed  CAS  Google Scholar 

  92. Gourlay SG. The pros and cons of transdermal nicotine. Med J Aust 1994; 160: 152–9

    PubMed  CAS  Google Scholar 

  93. Fagerström K-O, Sawe U, Tønnesen P. Therapeutic use of nicotine patches: efficacy and safety. J Smoking-Related Dis 1992; 3: 247–61

    Google Scholar 

  94. Silagy C, Mant D, Fowler G, et al. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994; 343: 139–42

    PubMed  CAS  Google Scholar 

  95. Orleans CT, Rimer BK, Cristinzio S, et al. A national survey of older smokers: treatment needs of a growing population. Health Psychol 1991; 10:343–51

    PubMed  CAS  Google Scholar 

  96. Transdermal nicotine study group. Transdermal nicotine for smoking cessation. JAMA 1991; 266: 3133–8

    Google Scholar 

  97. Kottke TE, Battista RN, DeFriese GH, et al. Attributes of successful smoking cessation interventions in medical practice. JAMA 1988; 259: 2882–9

    Google Scholar 

  98. Arnaot MR. Nicotine patches may not be safe. BMJ 1995; 310: 663–4

    PubMed  CAS  Google Scholar 

  99. Benowitz NL. Nicotine patches. BMJ 1995; 310: 1409–10

    PubMed  CAS  Google Scholar 

  100. Working group for the study of transdermal nicotine in patients with coronary disease. Arch Intern Med 1994; 154: 989–95

    Google Scholar 

  101. Hwang SL, Waldholt M. Heart attacks reported in patch users still smoking. Wall Street Journal: June 19, New York 1992

    Google Scholar 

  102. Brenner DE, Pethica D, Mickail HMI, et al. Surveillance of the cardiovascular safety of transdermal nicotine as smoking cessation aid [abstract]. Pharmacoepidemiol Drug Saf 1994 Aug; 3Suppl. 1:593

    Google Scholar 

  103. Broulik PD, Jarab J. The effect of chronic nicotine administration on bone minerai content in mice. Horm Metab Res 1993; 25: 219–21

    PubMed  CAS  Google Scholar 

  104. Baron JA, Kiel DP. Cigarette smoking and osteoporosis. J Smoking-Related Dis 1994: 5Suppl. 1: 69–74

    Google Scholar 

  105. Tønnesen P, Nørregaard J, Simonsen K, et al. A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. N Engl J Med 1991; 325: 311–5

    PubMed  Google Scholar 

  106. Russell MAH, Stapleton JA, Feyerabend C, et al. Targeting heavy smokers in general practice: randomised controlled trial of transdermal nicotine patches. BMJ 1993; 306: 1308–12

    PubMed  CAS  Google Scholar 

  107. Imperial Cancer Research Fund General Practice Research Group. Effectiveness of a nicotine patch in helping people stop smoking: results of a randomised trial in general practice. BMJ 1993; 306: 1304–8

    Google Scholar 

  108. Gourlay SG, Forbes A, Marriner T, et al. A randomised clinical trial of a second course of transdermal nicotine therapy. BMJ 1995; 311: 363–6

    PubMed  CAS  Google Scholar 

  109. Gourlay SG. Pharmacotherapies for smoking cessation [thesis]. Melbourne: Monash University, 1995

    Google Scholar 

  110. Sutherland G, Stapleton JA, Russell MAH, et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 1992; 340: 324–9

    PubMed  CAS  Google Scholar 

  111. Tønnesen P, Nørregaard J, Mikkelsen K, et al. A double-blind trial of a nicotine inhaler for smoking cessation. JAMA 1993; 269: 1268–71

    PubMed  Google Scholar 

  112. Fagerström KO, Schneider NG, Lunell E. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology 1993; 111: 271–7

    PubMed  Google Scholar 

  113. Kornitzer M, Boutsen M, Dramaix M, et al. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med 1995; 24: 41–7

    PubMed  CAS  Google Scholar 

  114. Dale LC, Hurt RD, Offord KP, et al. High dose nicotine patch therapy: percentage of replacement and smoking cessation. JAMA 1995; 274: 1353–8

    PubMed  CAS  Google Scholar 

  115. Jorenby DE, Smith SS, Fiore MC, et al. Varying nicotine patch dose and type of smoking cessation counselling. JAMA 1995; 274: 1347–52

    PubMed  CAS  Google Scholar 

  116. Tønnesen P, Fryd V, Hansen M, et al. Effect of nicotine chewing gum in combination with group counselling on the cessation of smoking. N Engl J Med 1988; 318: 15–8

    PubMed  Google Scholar 

  117. Sach DP, Benowitz NL, Bostrum AG, et al. Percent serum replacement and success of nicotine patch therapy [abstract]. Am J Respir Crit Care Med 1995; 151: A688

    Google Scholar 

  118. Killen JD, Fortmann SP, Newman B, et al. Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention. J Clin Consult Clin Psychol 1990; 58: 85–92

    CAS  Google Scholar 

  119. Daughton DM, Heatley SA, Prendergast JJ, et al. Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy: a randomized placebo-controlled, double-blind study. Arch Intern Med 1991; 151: 749–52

    PubMed  CAS  Google Scholar 

  120. Lee BL, Benowitz NL, Jacob III P. Cigarette abstinence, nicotine gum and theophylline disposition. Ann Intern Med 1987; 106: 553–5

    PubMed  CAS  Google Scholar 

  121. Brown CR, Jacob III P, Wilson M, et al. Changes in rate and pattern of caffeine metabolism after cigarette abstinence. Clin Pharm Ther 1988; 43: 488–91

    CAS  Google Scholar 

  122. Deanfield J, Wright C, Krikler S, et al. Cigarette smoking and the treatment of angina with propranolol, atenolol and nifedipine. N Engl J Med 1984; 310: 951–4

    PubMed  CAS  Google Scholar 

  123. Benowitz NL, Hall SM, Modin G. Persistent increase in caffeine concentrations in people who stop smoking. BMJ 1989; 298: 1075–6

    PubMed  CAS  Google Scholar 

  124. Kenford SL, Fiore MC, Jorenby DE, et al. Predicting smoking cessation: who will quit with and without the nicotine patch. JAMA 1994; 271: 589–94

    PubMed  CAS  Google Scholar 

  125. Stapleton JA, Russell MAH, Feyerabend C, et al. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction 1995; 90: 31–42

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of California, San Francisco, California, USA

    Steven G. Gourlay (National Heart Foundation of Australia Ralph Reader Overseas Research Fellow)

  2. Division of Clinical Pharmacology and Experimental Therapeutics, University of California, San Francisco, California, USA

    Neal L. Benowitz

Authors
  1. Steven G. Gourlay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neal L. Benowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gourlay, S.G., Benowitz, N.L. The Benefits of Stopping Smoking and the Role of Nicotine Replacement Therapy in Older Patients. Drugs & Aging 9, 8–23 (1996). https://doi.org/10.2165/00002512-199609010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199609010-00002

Keywords

Search

Navigation